Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Prostate Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 71 articles: HTML format Text format

Single Articles

May 2018
1. HAGGSTROM C, Van Hemelrijck M, Garmo H, Robinson D, et al
   Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and type 2 diabetes mellitus.
   Int J Cancer. 2018 May 9. doi: 10.1002/ijc.31587.
   PubMed     Text format     Abstract available
   
   
   April 2018
2. OKI R, Ito K, Suzuki R, Fujizuka Y, et al
   Long-term longitudinal changes in baseline PSA distribution and estimated prevalence of prostate cancer in male Japanese participants of population-based PSA screening.
   Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31560.
   PubMed     Text format     Abstract available
   
   
   
3. URBIOLA C, Santer FR, Petersson M, van der Pluijm G, et al
   Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer.
   Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31556.
   PubMed     Text format     Abstract available
   
   
   
4. DOAT S, Marous M, Rebillard X, Tretarre B, et al
   Prostatitis, other genitourinary infections and prostate cancer risk: Influence of non-steroidal anti-inflammatory drugs? Results from the EPICAP study.
   Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31565.
   PubMed     Text format     Abstract available
   
   
   March 2018
5. BELIC J, Graf R, Bauernhofer T, Cherkas Y, et al
   Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
   Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31397.
   PubMed     Text format     Abstract available
   
   
   
6. PORRETTI J, Dalton GN, Massillo C, Scalise GD, et al
   CLCA2 epigenetic regulation by CTBP1, HDACs, ZEB1, EP300 and miR-196b-5p impacts prostate cancer cell adhesion and EMT in metabolic syndrome disease.
   Int J Cancer. 2018 Mar 14. doi: 10.1002/ijc.31379.
   PubMed     Text format     Abstract available
   
   
   February 2018
7. CUI J, Wang Y, Dong B, Qin L, et al
   Pharmacological Inhibition of the Notch Pathway Enhances the Efficacy of Androgen Deprivation Therapy for Prostate Cancer.
   Int J Cancer. 2018 Feb 27. doi: 10.1002/ijc.31346.
   PubMed     Text format     Abstract available
   
   
   
8. QU S, Xue H, Dong X, Lin D, et al
   Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model.
   Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31310.
   PubMed     Text format     Abstract available
   
   
   
9. SHAO Y, Ye G, Ren S, Piao HL, et al
   Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer.
   Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31313.
   PubMed     Text format     Abstract available
   
   
   
10. FARRIS MS, Courneya KS, Kopciuk KA, McGregor SE, et al
    Post-diagnosis alcohol intake and prostate cancer survival: A population-based cohort study.
    Int J Cancer. 2018 Feb 13. doi: 10.1002/ijc.31307.
    PubMed     Text format     Abstract available
    
    
    
11. DAWE DE, Ye X, Czaykowski P, Jassal D, et al
    The effect of statin use on the incidence of prostate cancer: A population-based nested case-control study.
    Int J Cancer. 2018 Feb 6. doi: 10.1002/ijc.31295.
    PubMed     Text format     Abstract available
    
    
    January 2018
12. TOMIC K, Ventimiglia E, Robinson D, Haggstrom C, et al
    Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study.
    Int J Cancer. 2018 Jan 24. doi: 10.1002/ijc.31272.
    PubMed     Text format     Abstract available
    
    
    
13. ARTHUR R, Williams R, Garmo H, Holmberg L, et al
    Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study.
    Int J Cancer. 2018 Jan 11. doi: 10.1002/ijc.31256.
    PubMed     Text format     Abstract available
    
    
    
14. WU J, Wilson KM, Stampfer MJ, Willett WC, et al
    A 24-year prospective study of dietary alpha-linolenic acid and lethal prostate cancer.
    Int J Cancer. 2018 Jan 8. doi: 10.1002/ijc.31247.
    PubMed     Text format     Abstract available
    
    
    December 2017
15. LUO Y, Azad AK, Karanika S, Basourakos SP, et al
    Enzalutamide and CXCR7 inhibitor Combination Treatment Suppresses Cell Growth and Angiogenic Signaling in Castration-Resistant Prostate Cancer Models.
    Int J Cancer. 2017 Dec 26. doi: 10.1002/ijc.31237.
    PubMed     Text format     Abstract available
    
    
    
16. KHAN S, Hicks V, Colditz GA, Kibel AS, et al
    The association of weight change in young adulthood and smoking status with risk of prostate cancer recurrence.
    Int J Cancer. 2017 Dec 22. doi: 10.1002/ijc.31229.
    PubMed     Text format     Abstract available
    
    
    
17. RIDGE SM, Bhattacharyya D, Dervan E, Naicker SD, et al
    Secreted Factors from Metastatic Prostate Cancer Cells Stimulate Mesenchymal Stem Cell Transition to a Pro-tumourigenic 'Activated' State that Enhances Prostate Cancer Cell Migration.
    Int J Cancer. 2017 Dec 20. doi: 10.1002/ijc.31226.
    PubMed     Text format     Abstract available
    
    
    
18. UGGE H, Udumyan R, Carlsson J, Andren O, et al
    Acne in late adolescence and risk of prostate cancer.
    Int J Cancer. 2017 Dec 4. doi: 10.1002/ijc.31192.
    PubMed     Text format     Abstract available
    
    
    November 2017
19. GONZALEZ-MENENDEZ P, Hevia D, Mayo JC, Sainz RM, et al
    The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas?
    Int J Cancer. 2017 Nov 21. doi: 10.1002/ijc.31165.
    PubMed     Text format     Abstract available
    
    
    
20. REGER MK, Zollinger TW, Liu Z, Jones JF, et al
    Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2017 Nov 8. doi: 10.1002/ijc.31095.
    PubMed     Text format     Abstract available
    
    
    
21. BARRDAHL M, Canzian F, Gaudet MM, Gapstur SM, et al
    A comprehensive analysis of polymorphic variants in steroid hormone and IGF-1 metabolism and risk of in situ breast cancer: results from the Breast and Prostate Cancer Cohort (BPC3) Consortium.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31145.
    PubMed     Text format     Abstract available
    
    
    
22. DICKERMAN BA, Torfadottir JE, Valdimarsdottir UA, Wilson KM, et al
    Midlife metabolic factors and prostate cancer risk in later life.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31142.
    PubMed     Text format     Abstract available
    
    
    October 2017
23. SEIKKULA HA, Kaipia AJ, Ryynanen H, Seppa K, et al
    The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland.
    Int J Cancer. 2017 Oct 16. doi: 10.1002/ijc.31109.
    PubMed     Text format     Abstract available
    
    
    
24. HEIJNSDIJK EAM, Bangma CH, Borras JM, de Carvalho TM, et al
    Summary statement on screening for prostate cancer in Europe.
    Int J Cancer. 2017 Oct 12. doi: 10.1002/ijc.31102.
    PubMed     Text format     Abstract available
    
    
    
25. 
    Retraction: 'Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells' by Nobuyuki Kikuno, Hiroaki Shiina, Shinji Urakami, Ken Kawamoto, Hiroshi Hirata, Yuichiro Tanaka, Shahana Majid, Mikio Ig
    Int J Cancer. 2017;141:1492.
    PubMed     Text format     Abstract available
    
    
    August 2017
26. CHASIMPHA SJD, Parkin DM, Masamba L, Dzamalala CP, et al
    Three-year cancer incidence in Blantyre, Malawi (2008-2010).
    Int J Cancer. 2017;141:694-700.
    PubMed     Text format     Abstract available
    
    
    
27. KVALE R, Myklebust TA, Engholm G, Heinavaara S, et al
    Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975-2013.
    Int J Cancer. 2017 Aug 10. doi: 10.1002/ijc.30924.
    PubMed     Text format     Abstract available
    
    
    July 2017
28. LIN HM, Mahon KL, Weir JM, Mundra PA, et al
    A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer: Authors.
    Int J Cancer. 2017 Jul 25. doi: 10.1002/ijc.30903.
    PubMed     Text format     Abstract available
    
    
    
29. WANG B, Lo UG, Wu K, Kapur P, et al
    Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.
    Int J Cancer. 2017 Jul 19. doi: 10.1002/ijc.30893.
    PubMed     Text format     Abstract available
    
    
    
30. WANG K, Chen X, Bird VY, Gerke TA, et al
    Association between Age-Related Reductions in Testosterone and Risk of Prostate Cancer - An Analysis of Patients' Data with Prostatic Diseases.
    Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30882.
    PubMed     Text format     Abstract available
    
    
    
31. GU F, Zhang H, Hyland PL, Berndt S, et al
    Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
    Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30883.
    PubMed     Text format     Abstract available
    
    
    
32. SCHECHER S, Walter B, Falkenstein M, Macher-Goeppinger S, et al
    Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30864.
    PubMed     Text format     Abstract available
    
    
    June 2017
33. AL-QATATI A, Akrong C, Stevic I, Pantel K, et al
    Plasma microRNA signature is associated with risk stratification in prostate cancer patients.
    Int J Cancer. 2017 Jun 1. doi: 10.1002/ijc.30815.
    PubMed     Text format     Abstract available
    
    
    May 2017
34. DICKERMAN BA, Ahearn TU, Giovannucci E, Stampfer MJ, et al
    Weight change, obesity, and risk of prostate cancer progression among men with clinically localized prostate cancer.
    Int J Cancer. 2017 May 23. doi: 10.1002/ijc.30803.
    PubMed     Text format     Abstract available
    
    
    
35. WANG Y, Freedman JA, Liu H, Moorman PG, et al
    Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30787.
    PubMed     Text format     Abstract available
    
    
    April 2017
36. POUNIS G, Tabolacci C, Costanzo S, Cordella M, et al
    Reduction by coffee consumption of prostate cancer risk: Evidence from the Moli-sani cohort and cellular models.
    Int J Cancer. 2017 Apr 24. doi: 10.1002/ijc.30720.
    PubMed     Text format     Abstract available
    
    
    
37. PEREZ-CORNAGO A, Travis RC, Appleby PN, Tsilidis KK, et al
    Fruit and vegetable intake and prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Int J Cancer. 2017 Apr 17. doi: 10.1002/ijc.30741.
    PubMed     Text format     Abstract available
    
    
    
38. ROMAGUERA D, Gracia-Lavedan E, Molinuevo A, de Batlle J, et al
    Adherence to nutrition-based cancer prevention guidelines and breast, prostate and colorectal cancer risk in the MCC-Spain case-control study.
    Int J Cancer. 2017 Apr 5. doi: 10.1002/ijc.30722.
    PubMed     Text format     Abstract available
    
    
    March 2017
39. KAWADA T
    Dairy intake and prostate cancer survival.
    Int J Cancer. 2017 Mar 23. doi: 10.1002/ijc.30703.
    PubMed     Text format    
    
    
    February 2017
40. DOWNER MK, Batista JL, Mucci LA, Stampfer MJ, et al
    Dairy intake in relation to prostate cancer survival.
    Int J Cancer. 2017 Feb 10. doi: 10.1002/ijc.30642.
    PubMed     Text format     Abstract available
    
    
    January 2017
41. SHEN J, Li Z, Song Z, Chen J, et al
    Genome-wide two-locus interaction analysis identifies multiple epistatic SNP pairs that confer risk of prostate cancer: A cross-population study.
    Int J Cancer. 2017 Jan 25. doi: 10.1002/ijc.30622.
    PubMed     Text format     Abstract available
    
    
    
42. LUBIK AA, Nouri M, Truong S, Ghaffari M, et al
    Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.
    Int J Cancer. 2017;140:358-369.
    PubMed     Text format     Abstract available
    
    
    
43. HORI S, Wadhwa K, Pisupati V, Zecchini V, et al
    Loss of hSef promotes metastasis through up-regulation of EMT in prostate cancer.
    Int J Cancer. 2017 Jan 10. doi: 10.1002/ijc.30604.
    PubMed     Text format     Abstract available
    
    
    December 2016
44. FARRIS MS, Kopciuk KA, Courneya KS, McGregor SE, et al
    Identification and prediction of health-related quality of life trajectories after a prostate cancer diagnosis.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30586.
    PubMed     Text format     Abstract available
    
    
    November 2016
45. KUNUTSOR SK, Laukkanen JA
    Gamma-glutamyltransferase and risk of prostate cancer: Findings from the KIHD prospective cohort study.
    Int J Cancer. 2016 Nov 8. doi: 10.1002/ijc.30511.
    PubMed     Text format     Abstract available
    
    
    October 2016
46. HAGGSTROM C, Van Hemelrijck M, Zethelius B, Robinson D, et al
    Prospective study of Type 2 Diabetes Mellitus, anti-diabetic drugs, and risk of prostate cancer.
    Int J Cancer. 2016 Oct 22. doi: 10.1002/ijc.30480.
    PubMed     Text format     Abstract available
    
    
    
47. TRABERT B, Eldridge RC, Pfeiffer RM, Shiels MS, et al
    Pre-diagnostic circulating inflammation markers and endometrial cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
    Int J Cancer. 2016 Oct 22. doi: 10.1002/ijc.30478.
    PubMed     Text format     Abstract available
    
    
    
48. TAYLOR AE, Martin RM, Geybels MS, Stanford JL, et al
    Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis.
    Int J Cancer. 2016 Oct 14. doi: 10.1002/ijc.30462.
    PubMed     Text format     Abstract available
    
    
    
49. NAIR-SHALLIKER V, Yap S, Nunez C, Egger S, et al
    Adult body size, sexual history and adolescent sexual development, may predict risk of developing prostate cancer: Results from the New South Wales Cancer Lifestyle and Evaluation of Risk Study (CLEAR).
    Int J Cancer. 2016 Oct 14. doi: 10.1002/ijc.30471.
    PubMed     Text format     Abstract available
    
    
    September 2016
50. BRUNNER C, Davies NM, Martin RM, Eeles R, et al
    Alcohol Consumption and Prostate Cancer Incidence and Progression: A Mendelian Randomization Study.
    Int J Cancer. 2016 Sep 19. doi: 10.1002/ijc.30436.
    PubMed     Text format     Abstract available
    
    
    
51. WILSON KM, Markt SC, Fang F, Nordenvall C, et al
    Snus use, smoking and survival among prostate cancer patients.
    Int J Cancer. 2016 Sep 1. doi: 10.1002/ijc.30411.
    PubMed     Text format     Abstract available
    
    
    August 2016
52. CRAWLEY D, Garmo H, Rudman S, Stattin P, et al
    Association between duration and type of Androgen Deprivation Therapy and risk of diabetes in men with prostate cancer.
    Int J Cancer. 2016 Aug 25. doi: 10.1002/ijc.30403.
    PubMed     Text format     Abstract available
    
    
    June 2016
53. RAMBERG H, Grytli HH, Nygard S, Wang W, et al
    PBX3 is a putative biomarker of aggressive Prostate Cancer.
    Int J Cancer. 2016 Jun 7. doi: 10.1002/ijc.30220.
    PubMed     Text format     Abstract available
    
    
    May 2016
54. ZUCCHETTO A, Gini A, Shivappa N, Hebert JR, et al
    Dietary inflammatory index and prostate cancer survival.
    Int J Cancer. 2016 May 31. doi: 10.1002/ijc.30208.
    PubMed     Text format     Abstract available
    
    
    
55. BONILLA C, Lewis SJ, Rowlands MA, Gaunt TR, et al
    Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels.
    Int J Cancer. 2016 May 26. doi: 10.1002/ijc.30206.
    PubMed     Text format     Abstract available
    
    
    
56. THAMILSELVAN V, Menon M, Thamilselvan S
    Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants and Akt in preclinical models: New hope for patients with prostate cancer.
    Int J Cancer. 2016 May 20. doi: 10.1002/ijc.30189.
    PubMed     Text format     Abstract available
    
    
    April 2016
57. KENDEL F, Helbig L, Neumann K, Herden J, et al
    Patients' perceptions of mortality risk for localized prostate cancer vary markedly depending on their treatment strategy.
    Int J Cancer. 2016 Apr 2. doi: 10.1002/ijc.30123.
    PubMed     Text format     Abstract available
    
    
    March 2016
58. BURDELSKI C, Kleinhans S, Kluth M, Hube-Magg C, et al
    Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
    Int J Cancer. 2016;138:1199-206.
    PubMed     Text format     Abstract available
    
    
    February 2016
59. LAPI F, Levi M, Simonetti M, Cancian M, et al
    Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study.
    Int J Cancer. 2016 Feb 24. doi: 10.1002/ijc.30061.
    PubMed     Text format     Abstract available
    
    
    
60. BONN SE, Sjolander A, Tillander A, Wiklund F, et al
    Body mass index in relation to serum prostate-specific antigen levels and prostate cancer risk.
    Int J Cancer. 2016 Feb 23. doi: 10.1002/ijc.30052.
    PubMed     Text format     Abstract available
    
    
    
61. YU L, Toriseva M, Tuomala M, Seikkula H, et al
    Increased expression of fibroblast growth factor 13 (FGF13) in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.
    Int J Cancer. 2016 Feb 17. doi: 10.1002/ijc.30048.
    PubMed     Text format     Abstract available
    
    
    
62. RYBICKI BA, Rundle A, Kryvenko ON, Mitrache N, et al
    Methylation in Benign Prostate and Risk of Disease Progression in Men Subsequently Diagnosed with Prostate Cancer.
    Int J Cancer. 2016 Feb 10. doi: 10.1002/ijc.30038.
    PubMed     Text format     Abstract available
    
    
    
63. WANG Y, Jacobs EJ, Newton CC, McCullough ML, et al
    Lycopene, tomato products and prostate cancer-specific mortality among men diagnosed with nonmetastatic prostate cancer in the Cancer Prevention Study-II Nutrition Cohort.
    Int J Cancer. 2016 Feb 2. doi: 10.1002/ijc.30027.
    PubMed     Text format     Abstract available
    
    
    January 2016
64. MURTOLA TJ, Karppa EK, Taari K, Talala K, et al
    5-alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
    Int J Cancer. 2016 Jan 25. doi: 10.1002/ijc.30017.
    PubMed     Text format     Abstract available
    
    
    
65. SUDHAN DR, Pampo C, Rice L, Siemann DW, et al
    Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.
    Int J Cancer. 2016 Jan 12. doi: 10.1002/ijc.29992.
    PubMed     Text format     Abstract available
    
    
    December 2015
66. DYSHLOVOY SA, Menchinskaya ES, Venz S, Rast S, et al
    The marine triterpene glycoside frondoside A exhibits activity in vitro and in vivo in prostate cancer.
    Int J Cancer. 2015 Dec 22. doi: 10.1002/ijc.29977.
    PubMed     Text format     Abstract available
    
    
    
67. DE CARVALHO TM, Heijnsdijk EA, de Koning HJ
    Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) men.
    Int J Cancer. 2015 Dec 22. doi: 10.1002/ijc.29976.
    PubMed     Text format     Abstract available
    
    
    
68. WU K, Spiegelman D, Hou T, Albanes D, et al
    Associations between unprocessed red and processed meat, poultry, seafood and egg intake and the risk of prostate cancer: A pooled analysis of 15 prospective cohort studies.
    Int J Cancer. 2015 Dec 19. doi: 10.1002/ijc.29973.
    PubMed     Text format     Abstract available
    
    
    
69. THOMSEN FB, Folkvaljon Y, Garmo H, Robinson D, et al
    Risk of malignant melanoma in men with prostate cancer. Nationwide, population-based cohort study.
    Int J Cancer. 2015 Dec 14. doi: 10.1002/ijc.29961.
    PubMed     Text format     Abstract available
    
    
    
70. LYNCH HT, Kosoko-Lasaki O, Leslie SW, Rendell M, et al
    Screening for Familial and Hereditary Prostate Cancer.
    Int J Cancer. 2015 Dec 5. doi: 10.1002/ijc.29949.
    PubMed     Text format     Abstract available
    
    
    November 2015
71. CASTRO NAVA A, Cojoc M, Peitzsch C, Cirillo G, et al
    Development of novel radiochemotherapy approaches targeting prostate tumor progenitor cells using nanohybrids.
    Int J Cancer. 2015;137:2492-503.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: